drugset / Trial / NCT00653185
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the efficacy, safety and tolerability of SYR-472, once daily (QD), in subjects with Type 2 Diabetes Mellitus.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trelagliptin | Small molecule | 25 mg | Oral |
| Subject | Trelagliptin | Small molecule | 50 mg | Oral |
| Subject | Trelagliptin | Small molecule | 100 mg | Oral |
| Subject | Trelagliptin | Small molecule | 200 mg | Oral |